Stolt-Nielsen Limited Resolved the Cancellation of Treasury Shares
LONDON, October 6, 2021 – Stolt-Nielsen Limited (Oslo Børs: SNI) (the “Company”) today announced that the board of directors of the Company has resolved that 5,610,000 common shares and 1,402,500 founder's shares, previously held by the Company as treasury shares, shall be cancelled and thereafter be available for re-issue (the “Treasury Share Cancellation”).
Following the Treasury Share Cancellation, the Company holds 5,000,000 common shares, equal to 8.54% of the issued common shares, and 1,250,000 founder's shares, equal to 8.54% of the issued founder's shares, as treasury shares.
The Company's issued share capital after the Treasury Share Cancellation amounts to USD 58,538,426.95, divided into 58,523,796 common shares, each with a par value of USD 1.00, and 14,630,949 founder's shares, each with a par value of USD 0.001, in total 73,154,745 shares.
Notwithstanding the Treasury Share Cancellation, the Company's authorised share capital remains USD 81,250,000, divided into 65,000,000 common shares, each with a par value of USD 1.00, and 16,250,000 founder's shares, each with a par value of USD 0.001.
For additional information please contact:
Jens F. Grüner-Hegge
Chief Financial Officer
U.K. +44 (0) 20 7611 8985
j.gruner-hegge@stolt.com
Ellie Davison
Head of Corporate Communications
UK +44 (0) 20 7611 8926
e.davison@stolt.com
About Stolt-Nielsen Limited
Stolt-Nielsen (SNL or the ‘Company’) is a long-term investor and manager of businesses focused on opportunities in logistics, distribution and aquaculture. The Stolt-Nielsen portfolio consists of its three global bulk-liquid and chemicals logistics businesses – Stolt Tankers, Stolthaven Terminals and Stolt Tank Containers – Stolt Sea Farm and investments in LNG. Stolt-Nielsen Limited is listed on the Oslo Stock Exchange (Oslo Børs: SNI).
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Magna Announces 2024 Annual Meeting Results10.5.2024 00:00:00 CEST | Press release
AURORA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today announced voting results from its 2024 annual meeting of shareholders held on May 9, 2024. A total of 230,328,916 Common Shares or 80.18% of our issued and outstanding Common Shares were represented in person or by proxy at the meeting. Shareholders voted in favour of each item of business, as follows: a. Election of Directors Nominee Votes FORNomineeVotes FORMary S. Chan95.27%Mary Lou Maher98.16%Hon. V. Peter Harder98.97%William A. Ruh96.46%Jan R. Hauser99.73%Dr. Indira V. Samarasekera89.07%Seetarama S. Kotagiri (CEO)99.54%Matthew Tsien96.22%Jay K. Kunkel99.83%Dr. Thomas Weber95.08%Robert F. MacLellan97.63%Lisa S. Westlake95.29% b. Other Items of Business Item Votes FORReappointment of Deloitte99.65%Say on Pay85.36% Based on the voting results, all 12 nominees were re-elected to the Board, Deloitte was reappointed as independent auditor, and the “Say on Pay” resolution was approved –
Baltic Horizon Fund Consolidated Unaudited Results for Q1 20249.5.2024 22:55:00 CEST | Press release
Management Board of Northern Horizon Capital AS has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the three months of 2024. Our strategic ambitions Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from centrally located multi-functional assets aligned with our ‘Modern City Life’ strategy. These spaces are meticulously designed to ignite, elevate and enrich the lives of modern citizens and communities. The remaining results are expected to be derived primarily from government-rented premises and select suburban supermarkets and other segments. Our value propos
DBV Technologies to Participate in Upcoming Investor Conferences9.5.2024 22:30:00 CEST | Press release
Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Conference – May 13, 2024 Format: Fireside Chat Time: 11:00am ET Location: Hilton Midtown Hotel, New York, NY H.C. Wainwright BioConnect Conference – May 20, 2024 Format: Fireside Chat Time: 12:00pm ET Location: NASDAQ World Headquarters, New York, NY A live webcast of each presentation will be available on the Events page on the Investors section of the Company's website www.dbv-technologies.com. A replay will also be available for 90 days after each event. About DBV Technologies DBV Technologies is
King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia9.5.2024 17:06:04 CEST | Press release
RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care. Strategic investments in infrastructure, technology, and talent, have led to advancements revolutionizing patient care delivery and elevating the standards of healthcare locally. These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom. Central to these achievements, King Faisal Specialist Hospital & Research Centre (KFSH&RC), renowned for its specialized care and treatments across critical fields such as oncology, cardiology, organ transplantation, and genetics has positioned itself as a leader in specialized patient care, taking the charge towards a brighter, healthier future for the Kingdom. Through its commitment to pioneering digital health initiatives, comprehensive educational programs, and
Corza Medical Named “Best Overall MedTech Company” in 8th Annual MedTech Breakthrough Awards Program9.5.2024 16:30:00 CEST | Press release
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies WESTWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corza Medical today announced that it has been selected as the winner of the “Best Overall MedTech Company” award in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market. Corza Medical provides healthcare professionals with a platform of surgical technologies and features industry-leading brands. The company partners closely with clinicians and surgical providers to create a differentiated surgical experience through remarkable products and services that save time, money, and effort. Working with diverse healthcare providers ranging from hospital administrators to private practices, this exceptional medical device